Degarelix

證據等級: L5

預測適應症: 10 個

Degarelix: From Advanced Prostate Cancer to Hypertrichosis

One-Sentence Summary

Degarelix (Firmagon) is a GnRH receptor antagonist clinically used for advanced hormone-sensitive prostate cancer, acting by competitively blocking pituitary GnRH receptors to suppress testosterone production. The TxGNN model’s top prediction is Hypertrichosis, with a score of 99.99% — however, this prediction carries a known mechanism mismatch: hypertrichosis is defined as non-androgen-dependent excessive hair growth, distinct from androgen-driven hirsutism. No clinical trials and no relevant literature currently exist for this pairing; the prediction is rated L5 (model prediction only).

⚠️ Editorial Note: Among the 10 ranked predictions, Central Precocious Puberty 1 (Rank 9) is the only indication with genuine biological plausibility (GnRH-dependent pathophysiology directly targeted by Degarelix’s mechanism). The rank 1 prediction is reported here per protocol; see the Conclusion section for the actionable finding.

Quick Overview

Item	Content
Original Indication	Advanced prostate cancer (not registered in Taiwan; sourced from general medical knowledge — Taiwan regulatory data unavailable)
Predicted New Indication	Hypertrichosis
TxGNN Prediction Score	99.99%
Evidence Level	L5
Taiwan Market Status	✗ Not Marketed
Number of Authorizations	0
Recommended Decision	Hold

Why is This Prediction Reasonable?

Currently, detailed mechanism of action data is not available in the Evidence Pack (MOA field: Data Gap). Based on widely published pharmacology, Degarelix is a synthetic decapeptide GnRH receptor antagonist that competitively and reversibly blocks GnRH receptors in the anterior pituitary. This suppresses LH and FSH secretion, leading to a rapid and sustained reduction in serum testosterone — without the initial androgen surge (“flare effect”) seen with GnRH agonists. Its approved use is advanced hormone-sensitive prostate cancer, where testosterone suppression is the therapeutic goal.

The TxGNN model’s connection to hypertrichosis likely reflects the known role of androgens in regulating androgen-sensitive hair follicles. In theory, androgen suppression could reduce hair growth in conditions driven by excessive androgens (i.e., hirsutism). However, hypertrichosis is defined as excessive hair growth that is independent of androgen stimulation — it is a distinct clinical entity from hirsutism, driven by genetic factors, medications (e.g., minoxidil, phenytoin), or metabolic conditions. Degarelix’s androgen-lowering mechanism has no established pathway in non-androgen-dependent hypertrichosis.

The most probable explanation is that the TxGNN knowledge graph conflates hypertrichosis and hirsutism due to shared terminology in disease ontologies. The mechanism-indication pairing is biologically mismatched, and this prediction should not be pursued clinically. Critically, Rank 9 (Central Precocious Puberty 1) represents the one indication in this list where Degarelix’s GnRH-antagonist mechanism directly and specifically addresses the disease pathophysiology, and is the candidate warranting further investigation.

Clinical Trial Evidence

Currently no related clinical trials registered for Degarelix in hypertrichosis.

Literature Evidence

Currently no related literature available for Degarelix in hypertrichosis.

Taiwan Market Information

Degarelix is not registered in Taiwan (0 licenses, market status: 未上市). No authorization data is available for display.

For reference: Degarelix is marketed internationally as Firmagon (Ferring Pharmaceuticals) and has received approval in multiple jurisdictions including the EU and the United States for advanced prostate cancer. Taiwan regulatory data was not captured in this Evidence Pack.

Cytotoxicity

Degarelix is an antineoplastic agent (GnRH receptor antagonist) used for prostate cancer. This section applies.

Item	Content
Cytotoxicity Classification	Hormonal therapy / Endocrine therapy (GnRH receptor antagonist — not conventional cytotoxic)
Myelosuppression Risk	Low (hormonal therapy; not myelosuppressive by mechanism)
Emetogenicity Classification	Minimal to low
Monitoring Items	Serum testosterone, PSA, liver function tests, QTc interval (QT prolongation risk), bone mineral density with long-term use
Handling Protection	Standard pharmaceutical handling; no cytotoxic precautions required (not an alkylating agent or antimetabolite)

Safety Considerations

Safety data (warnings, contraindications, drug interactions) was not available in this Evidence Pack. Please refer to the Firmagon SmPC for complete safety information.

Conclusion and Next Steps

For Rank 1 — Hypertrichosis

Decision: Hold

Rationale: The mechanism-indication pairing is biologically mismatched: Degarelix suppresses androgens, but hypertrichosis is by definition non-androgen-dependent. No clinical trials or literature support this pairing. This prediction is very likely an artefact of the TxGNN knowledge graph conflating hypertrichosis with hirsutism.

Actions:

Do not proceed with hypertrichosis as a repurposing candidate.
Flag this disease pair as a known false positive for model calibration review.

⭐ Actionable Candidate — Rank 9: Central Precocious Puberty 1 (CPP1)

Decision: Research Question (Escalate to S1)

Rationale: Central precocious puberty (CPP) is a GnRH-dependent condition: premature activation of the hypothalamic-pituitary-gonadal (HPG) axis drives early puberty. Degarelix’s mechanism — direct, competitive GnRH receptor blockade at the pituitary — is precisely targeted at the upstream driver of CPP. Unlike the GnRH agonist standard of care (leuprolide, triptorelin), GnRH antagonists like Degarelix avoid the initial testosterone/estrogen flare seen at treatment initiation, potentially offering a faster onset of hormonal suppression. Related GnRH antagonists (cetrorelix, relugolix, linzagolix) have precedent in GnRH-axis indications beyond prostate cancer.

To proceed, the following is needed:

Systematic literature search specifically for “Degarelix AND precocious puberty” and “GnRH antagonist AND central precocious puberty” to characterize the existing evidence base (the current Evidence Pack returned 0 results, but the search query used only the exact indication name)
Safety profile review (obtain SmPC/TFDA label data — currently Blocking data gap DG001)
MOA documentation from DrugBank API (currently High severity data gap DG002)
Pediatric dosing and formulation assessment: Degarelix is currently available as a subcutaneous injection for adults; pediatric pharmacokinetics and acceptable injection frequency for children must be evaluated
Comparison with approved CPP treatments (leuprolide SC/IM, triptorelin) on efficacy endpoints and tolerability in pediatric populations
QTc prolongation risk assessment in pediatric patients (known adult concern)
Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.